Vor Biopharma Inc. (NYSE:VOR – Get Free Report) has earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $10.92.
Several analysts recently issued reports on VOR shares. Oppenheimer restated an “outperform” rating and issued a $10.00 price target (down from $15.00) on shares of Vor Biopharma in a research note on Monday, May 13th. Barclays reduced their target price on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research report on Friday, May 10th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Monday, May 13th.
Read Our Latest Stock Report on VOR
Institutional Inflows and Outflows
Vor Biopharma Price Performance
Shares of VOR opened at $0.99 on Wednesday. The firm has a market capitalization of $67.72 million, a PE ratio of -0.56 and a beta of -0.34. The company’s 50-day moving average is $0.99 and its 200-day moving average is $1.57. Vor Biopharma has a fifty-two week low of $0.70 and a fifty-two week high of $3.14.
Vor Biopharma (NYSE:VOR – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41). Analysts predict that Vor Biopharma will post -1.51 earnings per share for the current fiscal year.
About Vor Biopharma
Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Further Reading
- Five stocks we like better than Vor Biopharma
- What is the S&P 500 and How It is Distinct from Other Indexes
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- What is a Stock Market Index and How Do You Use Them?
- Lowe’s Stock: Hold Now, Buy it When it Dips
- How Can Investors Benefit From After-Hours Trading
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.